Gemtaz

Gemcitabine is a nucleoside metabolic inhibitor and antimetabolite chemotherapy drug that mimics cytidine, a building block of DNA, and interferes with DNA synthesis in rapidly dividing cells, leading to apoptosis primarily in cancer cells.[1] It is administered intravenously over 30 minutes and is approved for the treatment of advanced ovarian cancer (in combination with carboplatin), metastatic breast cancer after failure of prior anthracycline-containing therapy (with paclitaxel), non-small cell lung cancer (with cisplatin), and pancreatic adenocarcinoma as a single agent.[1] First approved by the U.S. Food and Drug Administration in 1996 for pancreatic cancer under the brand name Gemzar, gemcitabine has since become a standard component in regimens for multiple solid tumors due to its efficacy and relatively manageable toxicity profile.[1]